Inactive Instrument

Insiders Arsanis Inc Nasdaq

Equities

US0428731097

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

X4 Pharmaceuticals Insider Sold Shares Worth $181,573, According to a Recent SEC Filing	Nov. 03	MT
X4 Pharmaceuticals Insider Sold Shares Worth $168,371, According to a Recent SEC Filing	Nov. 03	MT
X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors	23-10-18	CI
X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer	23-08-09	CI
NeuroBo Pharmaceuticals Names Joseph Hooker Interim Chief Executive	23-01-18	MT
X4 Pharmaceuticals, Inc. Announces Executive Changes	22-11-03	CI
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer	22-10-26	CI
X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022	22-07-29	CI
Viridian Therapeutics Appoints Carrie Melvin to Fill New COO Role	22-06-23	MT
X4 Pharmaceuticals, Inc. Approves Resignation of Ren? Russo as Director	21-11-12	CI
X4 Pharmaceuticals, Inc. Appoints Françoise De Craecker to Board of Directors	21-10-19	CI
X4 Pharmaceuticals : Names Mary DiBiase Chief Operating Officer	21-09-08	MT
X4 Pharmaceuticals, Inc. Promotes Mary DiBiase, Ph.D. to Chief Operating Officer	21-09-08	CI
X4 Pharmaceuticals, Inc. Appoints Diego Cadavid, M.D., as Chief Medical Officer	20-12-14	CI
X4 Pharmaceuticals, Inc. Announces the Appointment of Art Taveras as Chief Scientific Officer	20-11-02	CI
X4 Pharmaceuticals, Inc. Announces Board Changes, Effective October 5, 2020	20-10-01	CI
X4 Pharmaceuticals, Inc. Announces Resignation of Renato Skerlj as Chief Scientific Officer, Effective October 2, 2020	20-09-11	CI
X4 Pharmaceuticals Promotes Renato Skerlj, to Chief Scientific Officer	20-06-11	CI
E. Lynne Kelley, M.D. Tenders Her Resignation as the Chief Medical Officer of X4 Pharmaceuticals, Inc., Effective April 3, 2020	20-03-20	CI
X4 Pharmaceuticals, Inc. Announces the Appointment of William E. Aliski as A Class II Director	19-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Arsanis Inc Nasdaq

Equities

US0428731097

Insiders

Filters